CTOs on the Move

PharmaPix

www.pharmpix.com

 
PharmaPix is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pharmpix.com
  • 1755 Park St Ste 200
    Naperville, IL USA 60563
  • Phone: 630.778.9866

Executives

Name Title Contact Details

Similar Companies

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.

Vascular Technology

Vascular Technology Incorporated is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Process Design

Process Design Corp. is a Carson City, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beth Israel Deaconess Hospital-Needham

BID Needham, part of Beth Israel Lahey Health, is focused on providing our patients with easy access to compassionate, safe and high-quality health care.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.